Actinium Pharmaceuticals Inc (ATNM) on Focus After Forming Head & Shoulders Chart Pattern

July 18, 2017 - By Marguerite Chambers

Investors sentiment decreased to 1 in 2016 Q4. Its down 1.14, from 2.14 in 2016Q3. It is negative, as 3 investors sold Actinium Pharmaceuticals Inc shares while 7 reduced holdings. 4 funds opened positions while 6 raised stakes. 5.73 million shares or 8.13% less from 6.24 million shares in 2016Q3 were reported.
Group One Trading Limited Partnership has 13,045 shares for 0% of their portfolio. Blackrock Institutional Communication Na invested in 559,831 shares or 0% of the stock. 7,000 were accumulated by Hartford Management. Geode Cap Management owns 151,287 shares. Creative Planning has 819 shares for 0% of their portfolio. Da Davidson Com, a Montana-based fund reported 112,000 shares. Susquehanna Intll Gru Llp, a Pennsylvania-based fund reported 32,574 shares. Sabby Mngmt Lc stated it has 0.04% in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM). Barclays Public Ltd Co reported 15,000 shares stake. Raymond James Fin Services Advsrs Incorporated reported 0% of its portfolio in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM). Dowling And Yahnke Llc invested in 0% or 22,870 shares. Bankshares Of New York Mellon Corporation owns 0% invested in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 49,084 shares. Kcg has invested 0% in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM). Two Sigma Securities Lc has 33,986 shares. Blackrock Fund Advsrs holds 0% or 104,967 shares in its portfolio.

Since June 15, 2017, it had 3 buys, and 0 selling transactions for $18,370 activity. 3,500 shares valued at $4,095 were bought by O’Loughlin Steve on Thursday, June 15. Shares for $5,550 were bought by Berger Mark Stanley.

The stock of Actinium Pharmaceuticals Inc (ATNM) formed H&S with $1.02 target or 4.00 % below today’s $1.06 share price. The 8 months Head & Shoulders indicates high risk for the $62.55 million company. It was reported on Jul, 18 by Faxor.com. If the $1.02 price target is reached, the company will be worth $2.50 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock increased 0.95% or $0.01 on July 17, reaching $1.06. About shares traded. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) has declined 15.34% since July 18, 2016 and is downtrending. It has underperformed by 32.04% the S&P500.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) Ratings Coverage

Among 2 analysts covering Actinum Pharma (NYSEMKT:ATNM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Actinum Pharma had 2 analyst reports since October 15, 2015 according to SRatingsIntel. Roth Capital initiated the shares of ATNM in report on Thursday, August 25 with “Buy” rating. The company was initiated on Thursday, October 15 by FBR Capital.

More notable recent Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) news were published by: Seekingalpha.com which released: “EMA says Actinium Pharma’s late-stage Iomab-B study sufficient for marketing …” on March 21, 2017, also Globenewswire.com with their article: “Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr …” published on May 17, 2017, Globenewswire.com published: “Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief …” on June 09, 2017. More interesting news about Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) were released by: Finance.Yahoo.com and their article: “Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017” published on February 10, 2017 as well as Globenewswire.com‘s news article titled: “Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of …” with publication date: December 19, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: